The Australian aesthetics market is one of the larger markets in Asia Pacific. This market approval provides access to the Ellansé™ dermal filler Family for both practitioners and patients in order to experience the added value of this unique dermal filler.

AQTIS Medical™ is delighted to have received this approval and is confident that together with its local distribution partner, Device Technologies Australia (www.device.com.au), Ellansé™ will soon be a well-recognized, valued product in the region.

Frost & Sullivan Technology Innovation Award Conferred on AQTIS Medical BV for its Pioneering Ellansé™. Read the analist quotes from Mr. Arjunvasan Ambigapathy on the Frost & Sullivan website by clicking the image below. You can also read some highlights below.

Quote 1:
“Despite high popularity of hyaluronic acid fillers among television anchors and celebrities, their usage for various procedures is entirely dependant on skills of surgeon and tolerance level of the patient. Ellansé™, a poly-caprolactone (PCL)-based dermal filler introduced by AQTIS Medical has been quite successful in establishing excellent safety profile and in enabling wide cosmetic applications. AQTIS Medical has tapped the potential of PCL to create one-of-a-kind polymeric microspheres that offer optimum viscosity, desired elasticity and uniform homogeneity.” says Arjunvasan Ambigapathy, Research Analyst at Frost & Sullivan

Quote 2:
“Ellansé™ delivers immediate and sustained performance with total bioresorbability through its four variants (S, M, L and E), who’s duration of action varies from 9 months up to 4 years. An unique aspect of STAT Technology embedded in Ellansé™ is that all four variants differ solely based on strength of their initial molecular weight of PCL
molecular polymer chains, accounting to its nature of controlled bioresorption and tuneable longevity.”, he noted.

Quote 3:
He also said, “Compared to several leading dermal fillers available in the market, Ellansé™ stands distinct in its property of tunable longevity and sustained performance, which are highly favorable for customer adoption. Aesthetic surgeons who perform procedures using other dermal fillers have observed positive effects on the use of Ellansé™, recommending it for most cosmetic applications.”

Quote 4:
“At a time when huge pricing competition is prevalent among large cosmetic companies, AQTIS Medical has taken efforts to commercialize their technology in several countries in Western Europe, South America, Middle East and Africa within a short time-frame; proving their capability to innovate and attain high customer retention rate.”, concludes
Mr.Ambigapathy

AQTIS Medical™ proudly accepted this prestigious award as recognition of the innovative technology presented in this dermal filler. The Frost & Sullivan report highlights some of the unique features that Ellansé offers the aesthetics market, and benefits it will bring to both health care professionals and patients.

Some highlights of the Frost & Sullivan report on the Ellansé™ dermal filler Family:

“This novel range of dermal fillers supports safe and cost-effective treatments in aesthetic medicine and surgery, through immediate and sustained performance, tunable longevity and total bioresorbability (STAT Technology™). Aesthetic surgeons have observed positive results from the use of Ellansé™, recommending it for most cosmetic applications.”

Ellansé™ has been designed to suit a wide range of customer needs – based on the desired duration of action, clients can choose the appropriate Ellansé™ variant. This enables its use across a wide spectrum of treatment procedures.

Unlike hyaluronic acid (HA) fillers, Ellansé™ offers superior bioresorption, coupled with maximum safety. Moreover, it delivers results that last twice as long as other leading fillers due to the fact that Ellansé™ acts as a biostimulator, helping patients generate their own new collagen (neocollagenesis). Importantly, during the final stages of bioresorption, the PCL microparticles lose mass and are completely resorbed by intracellular phagocytosis and excreted readily through the metabolic pathway.

The Technology Innovation Award is presented to the company that has excelled in the following criteria: uniqueness of technology, impact on functionality, impact on customer value and relevance of innovation to industry.”

“This novel range of dermal fillers supports safe and cost-effective treatments in aesthetic medicine and surgery, through immediate and sustained performance, tuneable longevity and total bioresorbability (STAT Technology™),” notes Frost & Sullivan Research Analyst Arjunvasan Ambigapathy. “Aesthetic surgeons have observed positive results from the use of Ellansé™, recommending it for most cosmetic applications.”

Ellansé™ comes in four variants (S, M, L, and E) based on the polymer chain strength of poly-caprolactone (PCL), with the duration of action varying from 9 months up to 4 years. PCL, a primary component of Ellansé™, is in the form of smooth microspheres, suspended homogenously in a tailored carboxymethylcellulose (CMC) gel-carrier and offers optimum viscosity, desired elasticity and uniform homogeneity.

Ellansé™ has been designed to suit a wide range of customer needs – based on the desired duration of action, clients can choose the appropriate polymer chain length of PCL. This enables its use across a wide spectrum of treatment procedures.

“Unlike other hyaluronic acid (HA) fillers, Ellansé™ offers superior bioresorption, coupled with maximum safety,” states Ambigapathy. “Moreover, it delivers results that last twice as long as other leading fillers due to the fact that Ellansé™ acts as a biostimulator, helping patients generate their own new collagen (neocollagenesis). Importantly, during the final stages of bioresorption, the PCL microparticles lose mass and are completely resorbed by intracellular phagocytosis and excreted readily through the metabolic pathway.”

Ellansé™ is indicated for a wide array of cosmetic (aesthetic) treatments, which include typical cosmetic thorns like volume-depleted areas and for soft tissue filling around nasolabial folds and marionette lines. The product is also widely used to enhance the zygomatic arch as well as soften wrinkles around the forehead and glabella.

The L and E strengths of Ellansé™ can be used to treat deep and profound wrinkles. In addition, they can be used to treat intense volumising issues such as lipoatrophy, cosmetic reconstructive surgery and can also be deployed for hand treatment.

The Technology Innovation Award is presented to the company that has excelled in the following criteria: uniqueness of technology, impact on functionality, impact on customer value and relevance of innovation to industry.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About AQTIS Medical BV
AQTIS Medical BV, the Netherlands is a privately held, medical device company specializing in research & development, manufacturing and commercialisation of innovative injectable medical devices. Ellansé™ dermal filler developed by AQTIS Medical embeds proprietary STAT Technology that consists of a unique set of bioresorbable medical polymer and gel formulations. AQTIS Medical has a distinctive competence in the modification and functionalization of bioresorbable polymers and gels in relation to longevity and other desired performance specifications. Ellansé™ is currently CE approved and used widely in most regions worldwide; In North America FDA approval is expected by the end of 2012.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six
continents. To join our Growth Partnership, please visit http://www.awards.frost.com.

http://www.frost.com/prod/servlet/press-release.pag?docid=223927775